がんワクチンの日本市場の評価：タイプ別、技術別、適応症別、エンドユーザー別、地域別、機会、予測（2018年度～2032年度）

日本のがんワクチンの市場規模は、2024年度の10億5,000万米ドルから2032年度に16億8,000万米ドルに達すると予測され、2025年度～2032年度の予測期間にCAGRで6%の成長が見込まれます。市場は、がんを予防し治療する必要性の高まりによって急速に拡大しています。ワクチンは罹患率とがんによる死亡を減少させるために不可欠です。市場の成長は、がん患者の増加、政府の強力な予防接種プログラム、大衆の意識の向上によって促進されています。mRNAワクチンや遺伝子組換えワクチンなど、ワクチン技術の開発が進み、開発と生産が加速しています。製薬企業やバイオテクノロジー企業による研究開発投資の増加は、HIVやがんなどの疾患に対する革新的なワクチンの開発につながっています。さらに、特に発展途上国では、政府機関が積極的に資金を提供し、大規模なワクチン接種キャンペーンを支援しています。バイオテクノロジー大手は、大きな成果を生み出すことができるよう結集しつつあります。例えば、Astellas Pharma Inc.は、抗CLDN18.2モノクローナル抗体であるVyloy（ゾルベツキシマブ）が、CLDN18.2陽性の切除不能な進行性および再発性の胃がん患者の治療薬として厚生労働省から承認されたと発表しました。Vyloyは、CLDN18.2を標的とした治療薬として、世界で初めて、そして唯一、規制当局から承認されています。有利な規制政策と医療費の増加が市場の拡大をさらに後押しします。老年人口の増加、新興経済国における医療インフラの開発、世界のワクチン接種率の拡大は、市場の長期的な成長を維持すると予測されます。

当レポートでは、日本のがんワクチン市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 日本のがんワクチン市場の見通し（2018年度～2032年度）

• 市場規模の分析と予測
  • 金額
  • 数量
• 市場シェアの分析と予測
  • タイプ別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 地域別
  • 市場シェア分析（上位5社とその他、金額）（2024年度）
• 市場マップ分析（2024年度）
  • タイプ別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 地域別

第5章 需給分析

第6章 バリューチェーン分析

第7章 ポーターのファイブフォース分析

第8章 PESTLE分析

第9章 価格分析

第10章 市場力学

• 市場促進要因
• 市場の課題

第11章 市場の動向と発展

第12章 規制枠組みとイノベーション

• 臨床試験
• 規制当局の承認

第13章 特許情勢

第14章 ケーススタディ

第15章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要企業上位10社の情勢
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company Limited
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Astellas Pharma Inc.
  • GlaxoSmithKline plc
  • Otsuka Holdings Co., Ltd.
  • Eisai Co., Ltd.
  • Shionogi & Co., Ltd.

第16章 戦略的提言

第17章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Cancer Vaccines Market, By Value, In USD Billion, FY2018-FY2032F
• Figure 2. Japan Cancer Vaccines Market, By Volume, In Million Units, FY2018-FY2032F
• Figure 3. Japan Cancer Vaccines Market Share (%), By Type, FY2018-FY2032F
• Figure 4. Japan Cancer Vaccines Market Share (%), By Technology, FY2018-FY2032F
• Figure 5. Japan Cancer Vaccines Market Share (%), By Indication, FY2018-FY2032F
• Figure 6. Japan Cancer Vaccines Market Share (%), By End-user, FY2018-FY2032F
• Figure 7. Japan Cancer Vaccines Market Share (%), By Region, FY2018-FY2032F
• Figure 8. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 9. By Technology Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 10. By Indication Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 11. By End-user Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 12. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2024

Japan cancer vaccines market is projected to witness a CAGR of 6% during the forecast period FY2025-FY2032, growing from USD 1.05 billion in FY2024 to USD 1.68 billion in FY2032. Japan cancer vaccines market is expanding rapidly, driven by the increasing need to prevent cancer, and cure it. Vaccines are essential for reducing morbidity and mortality from cancer. The market's growth is fueled by rising cases of cancer, strong government immunization programs, and increasing public awareness. Advancements in vaccine technology, such as mRNA and recombinant vaccines, are accelerating development and production. Increased R&D investments from pharmaceutical companies and biotech firms are leading to innovative vaccines for diseases such as HIV and cancer. Additionally, government organizations are actively funding and supporting large-scale vaccination campaigns, especially in developing countries. Biotechnology giants are coming together to be able to produce big results. For example, Astellas Pharma Inc., announced that Japan's Ministry of Health, Labor and Welfare (MHLW) approved Vyloy (zolbetuximab), an anti-CLDN18.2 monoclonal antibody to treat patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer. Vyloy is the first and only CLDN18.2-targeted therapy approved by any regulatory agency worldwide. Favorable regulatory policies and growing healthcare expenditures further support market expansion. The increasing geriatric population, rising healthcare infrastructure in emerging economies, and expanding global vaccination coverage are expected to sustain the market's long-term growth.

Research Breakthroughs Boosting Market Growth

One of the key factors propelling the Japan cancer vaccines market is research advancements. Innovative cancer vaccine research has been made possible by ongoing developments in immunotherapy, personalized medicine, and biotechnology. Japan has a solid background in medical research, with esteemed organizations and colleges focusing on the development of cancer vaccines. Novel antigens discovered as a result of advances in cancer immunology have made it possible to create vaccinations that specifically target and kill cancer cells. The development of innovative technologies has transformed the prevention and treatment of cancer, including mRNA and gene-based vaccinations. It is anticipated that these developments will treat different kinds of cancer, propelling market expansion. With Japan's focus on precision medicine and immuno-oncology, the country continues to make progress in understanding the molecular mechanisms of cancer, which is crucial for creating effective vaccines and therapies. For instance, NEC Bio B.V. presented interim results from a Phase 1 clinical trial of NECVAX-NEO1, an AI-driven personalized oral cancer vaccine in December 2024. The trial demonstrated the vaccine's safety and immunogenicity in patients with solid tumors, marking a significant advancement in personalized cancer immunotherapy.

Government Initiatives Fueling the Market Growth

In Japan, government measures have been instrumental in the expansion of the market for cancer vaccines. The Japanese government has continuously backed cancer research, contributing money to the creation of novel cancer treatments and vaccinations. The Ministry of Health, Labour, and Welfare (MHLW) in Japan has put more emphasis on cancer prevention in recent years, implementing public health initiatives and regulations to encourage early detection and immunization. In keeping with its goal of lowering cancer rates through immunization, the government has also started endorsing the HPV vaccine for the prevention of cervical cancer. A favorable environment for the development of cancer vaccines has also been created by Japan's significant investments in biotechnology and healthcare infrastructure. The government's commitment to reducing the cancer burden through innovation and healthcare reform is expected to drive the market's growth and accelerate the approval of new cancer vaccines. In September 2024, Japan, alongside the United States, Australia, and India, launched the Quad Cancer Moonshot Initiative. This collaborative effort seeks to reduce the cancer burden in the Indo-Pacific region by enhancing health infrastructure, expanding research, and improving access to cancer care.

Collaborative Environment Fueling the Market Growth

The market for cancer vaccines in Japan is expanding at a rapid pace due to growing alliances and partnerships between government agencies, academic institutions, and pharmaceutical businesses. The development of cancer vaccines is progressing more quickly due to partnerships between international and local actors that promote the sharing of resources, technology, and expertise. Japanese pharmaceutical giants like Takeda Pharmaceutical and Daiichi Sankyo are collaborating with foreign biotech companies and academic institutions to create innovative cancer vaccines. These collaborations lower the financial risk involved in developing a cancer vaccine while simultaneously enhancing access to cutting-edge technologies. Collaboration in clinical studies, regulatory approvals, and manufacturing procedures also guarantees that vaccines can be created effectively and get to market more quickly. The trend of collaboration enhances research, optimizes clinical testing, and brings diverse perspectives to the table, fueling innovation in cancer vaccines.

For instance, the Kawasaki Innovation Center for NanoMedicine (iCONM; Director: Kazunori Kataoka; Location: Kawasaki, Japan) have announced in collaboration with Tokyo Medical and Dental University, and Kyorin University that a group led by Prof. Satoshi Uchida, Principal Research Scientist of iCONM, has created a novel mRNA derivative and shown its high cellular immunity inducing anti-cancer activities in mice model. In tests employing melanoma and lymphoma model mice, this new mRNA exhibits strong anti-tumor effects, stimulates immune cells, and has double-stranded RNA in the form of comb teeth.

Future Market Scenario (FY2025 - FY2032F)

One of the main factors contributing to the anticipated growth of the cancer vaccines market is the increasing demand for treatment options to ensure patient safety by delivering the right quality of drug or any other such chemical product. The rising population and cases of cancer are also factors that will always propel the market's growth in the future. Given that technology is advancing, we can expect cutting-edge technology in the area. Players in this market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of cancer vaccines and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, the Japan Patent Office has sent Cleveland Clinic, a partner of Anixa Biosciences, Inc., a "Decision to Grant" notice for the patent application "Vaccine Adjuvants and Formulations." This new Japanese patent extends the claims for this novel breast cancer vaccine technology to an additional geographic region, beyond the U.S. and European patents previously awarded, as explained by Dr. Amit Kumar, Chairman and CEO of Anixa, in a July 17, 2024, press release.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan Cancer Vaccines Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Preventive Vaccines
    • 4.2.1.2. Therapeutic Vaccines
  • 4.2.2. By Technology
    • 4.2.2.1. Peptide-based vaccines
    • 4.2.2.2. Vector-based vaccines
    • 4.2.2.3. DNA/RNA-based vaccines
    • 4.2.2.4. Others
  • 4.2.3. By Indication
    • 4.2.3.1. Breast Cancer
    • 4.2.3.2. Lung Cancer
    • 4.2.3.3. Prostate Cancer
    • 4.2.3.4. Ovarian Cancer
    • 4.2.3.5. Others
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Specialty Centers
    • 4.2.4.3. Cancer Research Institutes
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North [Hokkaido and Tohoku]
    • 4.2.5.2. Central [Kanto and Chubu]
    • 4.2.5.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Type
  • 4.3.2. By Technology
  • 4.3.3. By Indication
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Value Chain Analysis

7. Porter's Five Forces Analysis

8. PESTLE Analysis

9. Pricing Analysis

10. Market Dynamics

• 10.1. Market Drivers
• 10.2. Market Challenges

11. Market Trends and Developments

12. Regulatory Framework and Innovation

• 12.1. Clinical Trials
• 12.2. Regulatory Approvals

13. Patent Landscape

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. Takeda Pharmaceutical Company Limited
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 15.3.2. Daiichi Sankyo Company Limited
  • 15.3.3. Merck & Co., Inc.
  • 15.3.4. Moderna, Inc.
  • 15.3.5. Chugai Pharmaceutical Co., Ltd.
  • 15.3.6. Astellas Pharma Inc.
  • 15.3.7. GlaxoSmithKline plc
  • 15.3.8. Otsuka Holdings Co., Ltd.
  • 15.3.9. Eisai Co., Ltd.
  • 15.3.10. Shionogi & Co., Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer